Premium
Dramatic response to brentuximab vedotin in refractory nontransformed CD 30 – mycosis fungoides allowing allogeneic stem cell transplant and long‐term complete remission
Author(s) -
Mahévas T.,
RamWolff C.,
Battistella M.,
Pennamen M.D.V.,
Rivet J.,
Brice P.,
Bagot M.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.17254
Subject(s) - mycosis fungoides , brentuximab vedotin , medicine , refractory (planetary science) , cd30 , vincristine , oncology , prednisone , lymphoma , dermatology , cyclophosphamide , chemotherapy , biology , astrobiology
Summary The erythrodermic ulcerated form of mycosis fungoides ( MF ) is exceptional, and treatment of refractory cases is challenging. Brentuximab vedotin ( BV ) is a monoclonal antibody combined with monomethyl auristatin E, recently approved for the treatment of refractory CD 30 + cutaneous T‐cell lymphoma. We report a case of refractory MF in a 56‐year‐old man with a long history of large‐plaque parapsoriasis, as revealed by psoriasiform erythroderma, treated initially with cyclophosphamide, doxorubicin, vincristine and prednisone ( CHOP ) polychemotherapy, inducing a 2‐year complete response. After relapse, interferon and gemcitabine were unsuccessful. Finally, treatment with BV was decided upon, despite the absence of CD 30 expression. After three infusions of BV 1·8 mg kg −1 , we achieved a complete and stable response, allowing an allogeneic stem cell transplant. The patient is still in complete remission, 19 months after the graft. This case illustrates the possibility of using BV in refractory CD 30 – MF as a salvage therapy.